Lv5
1250 积分 2023-02-08 加入
Regulation of tumour necrosis factor signalling: live or let die
13天前
已完结
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
24天前
已完结
Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study
1个月前
已完结
Single-cell and spatial transcriptomics of stricturing Crohn’s disease highlights a fibrosis-associated network
1个月前
已完结
Digestive Disease Week 2025
1个月前
已完结
CD30L is involved in the regulation of the inflammatory response through inducing homing and differentiation of monocytes via CCL2/CCR2 axis and NF-κB pathway in mice with colitis
2个月前
已完结
RIPK2 as a promising druggable target for autoimmune diseases
2个月前
已完结
RIP kinases as modulators of inflammation and immunity
2个月前
已完结
Role of CCL25/CCR9 in immune homeostasis and disease
5个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
5个月前
已完结
皖公网安备34019202002308
